BACKGROUND: The metabolic syndrome is a risk factor for the development of renal and vascular complications. Dietary protein intake aggravates renal injury in Zucker obese rats, a model of the metabolic syndrome. This study investigated whether dietary protein intake enhances renal and vascular injuries by oxidative stress, and assessed effects of olmesartan, an angiotensin II type 1 receptor blocker, in this model. METHODS: Zucker obese rats were fed either a standard protein diet, high protein diet (OHP), or high protein diet containing olmesartan or hydralazine for 12 weeks. We examined the glomerulosclerosis score, endothelium-dependent relaxation response in the aorta, 4-hydroxy-2-nonenal (HNE) contents in the kidney and aorta, and mRNA expression of NAD(P)H oxidase components (p22phox and p47phox) in the renal cortex. RESULTS: The OHP rats developed proteinuria, glomerulosclerosis, and endothelial dysfunction. Olmesartan prevented the development of all these damages in OHP rats, whereas hydralazine improved only glomerulosclerosis. The high protein diet also augmented HNE accumulation in glomeruli, renal arteries, and aortas, and increased the mRNA expressions of p22phox and p47phox in the renal cortex in obese rats. Olmesartan, but not hydralazine, inhibited all these changes. CONCLUSIONS: These results suggested that increased dietary protein intake exacerbates renal and vascular injuries, and augments oxidative stress in a rat model of the metabolic syndrome. Olmesartan ameliorated these injuries, presumably through its antioxidative effects, whereas hydralazine improved only glomerulosclerosis through its antihypertensive action. Dietary protein-enhanced injuries in the metabolic syndrome may be associated with hypercholesterolemia and the activated renin-angiotensin system.
BACKGROUND: The metabolic syndrome is a risk factor for the development of renal and vascular complications. Dietary protein intake aggravates renal injury in Zucker obeserats, a model of the metabolic syndrome. This study investigated whether dietary protein intake enhances renal and vascular injuries by oxidative stress, and assessed effects of olmesartan, an angiotensin II type 1 receptor blocker, in this model. METHODS: Zucker obeserats were fed either a standard protein diet, high protein diet (OHP), or high protein diet containing olmesartan or hydralazine for 12 weeks. We examined the glomerulosclerosis score, endothelium-dependent relaxation response in the aorta, 4-hydroxy-2-nonenal (HNE) contents in the kidney and aorta, and mRNA expression of NAD(P)H oxidase components (p22phox and p47phox) in the renal cortex. RESULTS: The OHP rats developed proteinuria, glomerulosclerosis, and endothelial dysfunction. Olmesartan prevented the development of all these damages in OHP rats, whereas hydralazine improved only glomerulosclerosis. The high protein diet also augmented HNE accumulation in glomeruli, renal arteries, and aortas, and increased the mRNA expressions of p22phox and p47phox in the renal cortex in obeserats. Olmesartan, but not hydralazine, inhibited all these changes. CONCLUSIONS: These results suggested that increased dietary protein intake exacerbates renal and vascular injuries, and augments oxidative stress in a rat model of the metabolic syndrome. Olmesartan ameliorated these injuries, presumably through its antioxidative effects, whereas hydralazine improved only glomerulosclerosis through its antihypertensive action. Dietary protein-enhanced injuries in the metabolic syndrome may be associated with hypercholesterolemia and the activated renin-angiotensin system.
Authors: Deok Ho Choi; Yun Jung Lee; Hyun Cheol Oh; Ying Lan Cui; Jin Sook Kim; Dae Gill Kang; Ho Sub Lee Journal: J Med Food Date: 2011-11-14 Impact factor: 2.786
Authors: Lisette E G Hubens; Willemien L Verloop; Jaap A Joles; Peter J Blankestijn; Michiel Voskuil Journal: Curr Hypertens Rep Date: 2013-08 Impact factor: 5.369
Authors: José Luis Miguel-Carrasco; Ana Baltanás; Carolina Cebrián; María U Moreno; Begoña López; Nerea Hermida; Arantxa González; Javier Dotor; Francisco Borrás-Cuesta; Javier Díez; Ana Fortuño; Guillermo Zalba Journal: Oxid Med Cell Longev Date: 2012-06-03 Impact factor: 6.543
Authors: So Min Lee; Yun Jung Lee; Jung Hoon Choi; Min Chul Kho; Jung Joo Yoon; Sun Ho Shin; Dae Gill Kang; Ho Sub Lee Journal: BMC Complement Altern Med Date: 2014-11-22 Impact factor: 3.659
Authors: Jung Joo Yoon; Yun Jung Lee; Ok Ju Park; So Min Lee; Yong Pyo Lee; Nam Geun Cho; Dae Gill Kang; Ho Sub Lee Journal: Evid Based Complement Alternat Med Date: 2013-08-25 Impact factor: 2.629